BlinkLab
AI-powered, smartphone-based diagnostic aids for neurodevelopmental conditions, initially autism and ADHD.
Website: https://www.blinklab.org/
Cover Block
From the public record
| Name | BlinkLab |
| Tagline | AI-powered, smartphone-based diagnostic aids for neurodevelopmental conditions, initially autism and ADHD. [BlinkLab] |
| Headquarters | Delft, Netherlands |
| Founded | 2021 |
| Stage | Public |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | $10M+ (total disclosed ~$16,600,000) |
Links
From the public record
- Website: https://www.blinklab.org/
- LinkedIn: https://www.linkedin.com/company/blinklab-neuro-behavioral-testing/
- App Store: https://apps.apple.com/us/app/blinklab-dx1/id6738943245
Confirmed across multiple sources -- Company website and public app store listing confirmed.
The Short Version
From the public record
BlinkLab is a public digital-health company developing smartphone-based diagnostic aids for neurodevelopmental conditions, a notable attempt to introduce scalable, objective measurement into a field dominated by subjective, clinician-intensive assessments [BlinkLab]. The company's lead product, Dx1, uses a smartphone's sensors and AI to analyze reflex-based measures as an aid for clinicians diagnosing autism, with a pivotal FDA 510(k) trial underway and a submission targeted for the second half of 2026 [ASX, October 2025], [Medpath, 2026].
Founded in 2021 as a Princeton University spinout, the company commercializes neuroscience research on eyeblink conditioning and sensorimotor reflexes, originating from work by co-founder and CEO Henk-Jan Boele, an assistant professor at Erasmus University Medical Centre and visiting researcher at the Princeton Neuroscience Institute [BlinkLab]. The founding team blends clinical neuroscience and technical development, with co-founders Peter Boele as CTO and Bas Koekkoek, a neuroscientist at Erasmus MC, as CSO [LinkedIn, 2026].
Capitalization has progressed through public markets, with an April 2024 IPO on the ASX raising A$7 million and subsequent placements in 2025 and 2026 raising an additional A$25.16 million (estimated) to fund the regulatory pathway and commercial preparation [Intelligent Investor, 2026], [News Hub, 2025], [ASX, April 2026]. The business model is B2B, targeting pediatric clinics and research institutions, with early deployment partners including North Shore Pediatric Therapy in Chicago and major academic centers like Vanderbilt and Seattle Children's for validation studies [Investing News, February 2025].
Over the next 12-18 months, the critical watch points are the completion of the pivotal FDA trial, the subsequent 510(k) submission and regulatory decision, and the initial commercial rollout strategy for Dx1, which will test the company's transition from a research-focused entity to a commercial diagnostics provider.
Single-source, plausible -- Core company facts and funding rounds are confirmed via ASX announcements and company materials; some product performance metrics are sourced solely from the company.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Public |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $10M+ (total disclosed ~$16.6M) |
The Company in Brief
From the public record
BlinkLab was founded in 2021 as a Princeton University startup, though its underlying technology traces back to a 2018 research project that developed the first smartphone-based neurometric application [BlinkLab]. The company is headquartered in Delft, Netherlands, and maintains a remote-first operational model, though its core team of neuroscientists, medical doctors, and software developers is based there [BlinkLab].
Key corporate milestones have centered on capital formation and regulatory advancement. The company listed on the Australian Securities Exchange (ASX:BB1) on April 4, 2024, raising A$7 million in its initial public offering [Intelligent Investor, 2026], [Investing News, 2026]. This was followed by a series of private placements: an A$7.66 million raise in February 2025 [Investing News, February 2025], and a significantly larger A$17.5 million (before costs) placement in April 2026, which the company stated was oversubscribed by institutional investors [ASX, April 2026]. The proceeds from these rounds are earmarked for advancing the company's lead product, BlinkLab Dx1, toward FDA regulatory submission and commercialization [ASX, April 2026].
Single-source, plausible -- Company narrative and ASX announcements provide a consistent timeline, but some early funding details lack independent corroboration.
What They Have Built
Mixed sourcing
BlinkLab's core product is a smartphone-based diagnostic aid, a Software as a Medical Device (SaMD) platform that uses the device's built-in sensors to capture objective, reflex-based measures during a structured test administered to a child [PUBLIC] [BlinkLab]. The company's lead application, BlinkLab Dx1, is designed to support clinicians in the assessment of autism spectrum disorder (ASD) in children as young as 18 months old [PUBLIC] [BlinkLab]. The system analyzes a suite of behavioral and physiological responses, including facial reflexes, eye and eyelid movements, startle responses, postural stability, and vocal responses, to generate a quantitative data point for the clinician [PUBLIC] [mycarrollcountynews.com]. The underlying scientific approach leverages decades of neuroscience research on eyeblink conditioning, a method for examining cerebellar function, which the company has translated into a scalable digital format [PUBLIC] [BlinkLab].
The platform's architecture is built to meet regulatory standards for a diagnostic aid. BlinkLab has publicly detailed its progress toward U.S. Food and Drug Administration (FDA) 510(k) clearance for Dx1 [PUBLIC] [mycarrollcountynews.com]. The company has completed a pre-submission meeting with the FDA, which agreed on a pivotal study design and confirmed a minimum performance threshold of greater than 65% for both sensitivity and specificity [PUBLIC] [ASX, October 2025]. A pilot study with 485 participants reportedly achieved sensitivity of 83.7% and specificity of 84.7%, exceeding those agreed thresholds [PUBLIC] [ASX, October 2025]. As of 2026, the company was conducting a double-blinded, multi-center pivotal validation study designed to support a 510(k) submission planned for the second half of the year [PUBLIC] [Medpath, 2026].
BlinkLab has also indicated it is developing a second product, Dx2, which extends the same smartphone-based diagnostic architecture to Attention-Deficit/Hyperactivity Disorder (ADHD) [PUBLIC] [FNArena.com, 2024]. The company states its platform is built for a range of neurodevelopmental conditions, including schizophrenia, though autism and ADHD are the initial focus [PUBLIC] [Pearler, 2026]. A recent European study on ADHD delivered preliminary results showing 82% sensitivity and 83% specificity relative to a clinical reference standard [PUBLIC] [BlinkLab]. From a technical execution standpoint, the company has showcased its FDA-grade iOS development expertise, indicating a focus on building robust, regulated mobile applications [PUBLIC] [The Globe and Mail / TipRanks, September 2026].
Single-source, plausible -- Key performance metrics and regulatory pathway details are sourced from company announcements and ASX filings; independent clinical publication of the pivotal trial data is pending.
Market Size and Demand
From the public record The market for objective, scalable diagnostic tools in neurodevelopment is defined by a persistent and costly clinical bottleneck, creating a clear opening for technology that can augment, rather than replace, specialist expertise.
Quantifying the total addressable market for diagnostic aids is challenging, as it sits at the intersection of pediatric healthcare, behavioral assessment, and digital health software. No third-party TAM analysis specific to AI-powered autism diagnostic aids was identified in the cited research. For an analogous market reference, the global autism spectrum disorder treatment market was valued at approximately $3.5 billion in 2023 and is projected to grow at a compound annual rate of 4.5% through 2030, according to a Grand View Research report cited by multiple industry publications [Grand View Research, 2023]. This figure, however, encompasses pharmaceuticals and behavioral therapies, not diagnostic tools. The specific opportunity for BlinkLab is better framed by the underlying demand drivers: lengthy wait times for specialist evaluation, which can exceed 12 months in many regions, and the high cost of traditional, observation-heavy diagnostic processes that require significant clinician hours.
Demand is propelled by several converging tailwinds. First, diagnostic criteria for conditions like autism and ADHD have broadened and formalized over recent decades, increasing the recognized prevalence and the corresponding clinical assessment burden. Second, there is a well-documented shortage of child psychiatrists and developmental pediatricians, particularly outside major urban centers. Third, both public and private payers are increasingly focused on cost containment in healthcare, creating incentives for tools that can make the diagnostic process more efficient without compromising accuracy. BlinkLab's smartphone-based wedge directly addresses these pressures by offering a potential method to standardize data collection and provide quantitative metrics to support, not replace, the clinician's judgment.
Key adjacent markets include the broader digital therapeutics and remote patient monitoring sectors, which have seen accelerated adoption and regulatory pathways, particularly since 2020. Substitute markets are the status quo: the existing ecosystem of paper-based questionnaires, observational checklists, and the time of highly trained specialists. The primary regulatory force is the U.S. Food and Drug Administration's 510(k) clearance pathway for Software as a Medical Device (SaMD), which BlinkLab is pursuing. Success here would not only grant market access but also serve as a significant validation and reimbursement credential. Macro forces are mixed; while healthcare budgets face pressure, public awareness and advocacy for early childhood developmental support remain strong, potentially sustaining demand for improved diagnostic infrastructure.
| Metric | Value |
|---|---|
| Autism Treatment Market (Analogous) 2023 | 3.5 $B |
| Projected CAGR 2023-2030 | 4.5 % |
The available sizing data, while not directly applicable to diagnostic aids, illustrates the scale of the overall therapeutic market BlinkLab aims to enter upstream. The growth rate suggests a stable, rather than explosive, underlying sector, where efficiency gains could be highly valued.
Single-source, plausible -- Market sizing is for an adjacent sector (treatment) from a single third-party report. Demand drivers are inferred from industry-wide challenges not uniquely cited for BlinkLab.
Who Else Is Fighting for This
Mixed sourcing
BlinkLab operates in a specialized niche where the primary competition is not other smartphone apps but the established, labor-intensive clinical assessment process it aims to augment. The company's initial wedge is against the status quo of observation-based diagnosis, not a crowded field of direct digital replicas.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| BlinkLab | AI-powered smartphone diagnostic aid for autism & ADHD. | Public (ASX:BB1). ~$16.6M total disclosed funding. | Pursuing FDA 510(k) clearance for a reflex-based, smartphone-captured diagnostic aid. | [BlinkLab], [ASX, April 2026] |
| Cognoa | Digital diagnostic aid for autism spectrum disorder. | Private. Raised ~$116M as of 2023. | Holds FDA De Novo authorization for its Canvas Dx product, a software-only diagnostic aid. | [Crunchbase, 2023] |
The competitive map segments into three tiers. First, the incumbent standard of care: multi-disciplinary clinical evaluations conducted by specialists, which are the gold standard but face severe access bottlenecks and high cost. Second, FDA-authorized digital diagnostic aids, where Cognoa is the only direct, cleared competitor with its Canvas Dx product [Crunchbase, 2023]. Third, a broader set of adjacent substitutes and future entrants, including telehealth platforms offering preliminary screenings, research tools from academic institutions, and a growing number of digital phenotyping startups targeting other neurodevelopmental conditions.
BlinkLab's defensible edge today is rooted in its specific scientific approach and regulatory pathway. The company's technology is based on decades of neuroscience research into eyeblink conditioning and cerebellar function, originating from Princeton [BlinkLab]. This provides a credible, patent-protected foundation distinct from the behavioral analysis algorithms used by others. Its edge is also procedural: the company has secured FDA agreement on its pivotal study design and performance thresholds, a significant regulatory milestone that creates a time and capital barrier for new entrants [ASX, October 2025]. However, this edge is perishable. It hinges entirely on successful 510(k) submission and clearance, expected in late 2026 [Medpath, 2026]. Without the FDA label, the product remains a research tool.
The company is most exposed in commercialization and market access. Cognoa's first-mover advantage with an already-cleared product provides a head start in building payer relationships and integrating into clinical workflows [Crunchbase, 2023]. BlinkLab's public-market capitalization provides growth capital but may also impose quarterly scrutiny that pressures commercial execution ahead of revenue. Furthermore, the company's focus on a smartphone-based, clinician-administered test could face channel competition from fully remote, parent-administered assessment tools that are simpler to deploy at scale, even if they serve a different, screening-oriented purpose.
The most plausible 18-month scenario centers on regulatory outcomes. If BlinkLab secures FDA clearance on schedule and its sensitivity/specificity data hold in the pivotal trial, it becomes a validated second mover with a technologically distinct offering, likely competing with Cognoa on cost and clinical workflow integration. In this scenario, companies relying solely on observational screening without a diagnostic aid claim would lose relevance in the specialist referral pathway. Conversely, if regulatory timelines slip or the pivotal data disappoint, BlinkLab would cede ground, and the winner would be the incumbent standard of care, reinforced by the difficulty of translating novel biomarkers into accepted clinical practice.
Single-source, plausible -- Competitor data is partially corroborated; BlinkLab's regulatory timeline is company-stated.
Opportunity
From the public record The prize for BlinkLab is a foundational position in a global, multi-billion dollar market for objective, scalable diagnostic tools in neurodevelopment, a field still dominated by subjective, clinician-intensive assessments.
The headline opportunity for BlinkLab is to become the first widely adopted, FDA-cleared digital biomarker platform for pediatric behavioral health, establishing a new standard of care for autism and ADHD diagnosis. This outcome is reachable because the company has already defined a clear regulatory pathway with the FDA [ASX, October 2025], secured clinical validation partnerships with major research institutions [Investing News, February 2025], and demonstrated pilot data that exceeds the agreed performance thresholds for clearance [BlinkLab]. The core bet is that a low-cost, smartphone-based diagnostic aid can scale into the massive gap between the demand for timely assessments and the limited supply of specialized clinicians, a wedge that is already being tested in real-world registrational studies.
Two distinct growth scenarios outline plausible paths to scale. The first is a direct, regulated medical device route, while the second explores a broader platform expansion.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Regulatory Standard-Bearer | Dx1 secures FDA 510(k) clearance as an autism diagnostic aid, becoming the first smartphone-based tool of its kind. Adoption is driven by clinical guidelines and payer reimbursement, starting with the network of research centers already in the pivotal trial. | Successful FDA submission and clearance in the second half of 2026, as planned [Medpath, 2026]. | The FDA has already agreed to the study design and performance thresholds [ASX, October 2025], and the company has enrolled a pivotal trial across 10 U.S. research centers [BlinkLab]. |
| Platform Expansion into ADHD | Following the autism regulatory blueprint, the company rapidly deploys Dx2 for ADHD, leveraging the same smartphone-based architecture and clinical partnerships to address another high-prevalence condition. | Positive results from the European ADHD study, which showed 82% sensitivity and 83% specificity [BlinkLab], are replicated in a U.S. pivotal trial. | The underlying technology platform is designed to be condition-agnostic [Pearler, 2026], and the recent A$17.5 million capital raise was explicitly earmarked to expand the ADHD program [ASX, April 2026]. |
Compounding for BlinkLab would manifest as a clinical-data flywheel and a distribution network effect. Each new clinical deployment generates proprietary datasets of reflex measures, which are used to refine the machine learning models, potentially improving accuracy and expanding the platform's diagnostic scope. Concurrently, every research center or pediatric clinic that adopts the tool for studies becomes a potential commercial site and a reference for broader health system adoption. Early signs of this flywheel are visible in the progression from a single pilot site to a multi-center FDA trial network that includes institutions like Vanderbilt and Seattle Children’s [BlinkLab].
In terms of the size of the win, a credible comparable is Cognoa, a privately held company developing an FDA-authorized AI-based diagnostic aid for autism. While Cognoa's valuation is not public, its authorization and commercial launch signal a market willing to adopt novel digital tools. If BlinkLab executes the Regulatory Standard-Bearer scenario, it could capture a meaningful portion of the U.S. autism diagnostic aid market, which involves millions of annual assessments. A platform that successfully expands into ADHD could address a total addressable market several times larger. The company's ability to raise significant capital post-IPO (A$17.5 million in April 2026 [ASX, April 2026]) suggests institutional investor belief in this potential scale, though the ultimate outcome hinges entirely on regulatory success and subsequent commercial execution.
Single-source, plausible -- Opportunity framing is based on confirmed regulatory plans and partnerships, but market size and valuation comparables are not fully quantified in public sources.
Sources
From the public record
[BlinkLab] BlinkLab | Revolutionizing Developmental Diagnostics and Care | https://www.blinklab.org/
[ASX, October 2025] ASX Announcement | https://announcements.asx.com.au/asxpdf/20251024/pdf/06yq5q4n4n6q6v.pdf
[Medpath, 2026] Medpath Article | https://medpath.com.au/article/blinklab-targets-fda-submission-in-second-half-of-2026/
[LinkedIn, 2026] Peter Boele - Co-founder and CTO at BlinkLab | https://nl.linkedin.com/in/peter-boele-0a1b72a7
[Intelligent Investor, 2026] Intelligent Investor Report | https://www.intelligentinvestor.com.au/blinklab-asx-bb1-ipo-report
[Investing News, 2026] Investing News Article | https://investingnews.com/blinklab-asx-bb1-listing/
[News Hub, 2025] News Hub Article | https://newshub.co.nz/article/business/blinklab-announces-successful-placement/
[ASX, April 2026] ASX Announcement - Placement | https://announcements.asx.com.au/asxpdf/20260416/pdf/06yjznyrpj7xt2.pdf
[Investing News, February 2025] North Shore Pediatric Therapy in Chicago Joins BlinkLab’s US Registrational Study | https://investingnews.com/north-shore-pediatric-therapy-in-chicago-joins-blinklabs-us-registrational-study/
[mycarrollcountynews.com] My Carroll County News Article | https://www.mycarrollcountynews.com/news/business/article_blinklab-fda-trial-design-2025-10-24.html
[FNArena.com, 2024] FNArena Article | https://www.fnarena.com/index.php/2024/12/05/blinklab-dx2-adhd-program/
[Pearler, 2026] Pearler Article | https://pearler.com/stock/bb1/blinklab
[The Globe and Mail / TipRanks, September 2026] BlinkLab Showcases FDA-Grade iOS Expertise at Leading Apple Developer Conference | https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4669787/blinklab-showcases-fda-grade-ios-expertise-at-leading-apple-developer-conference/
[Grand View Research, 2023] Grand View Research Report | https://www.grandviewresearch.com/industry-analysis/autism-spectrum-disorder-treatment-market
[Crunchbase, 2023] Cognoa Company Profile | https://www.crunchbase.com/organization/cognoa
Articles about BlinkLab
- BlinkLab's Smartphone Autism Test Clears a Key FDA Threshold — The publicly traded digital health startup is now enrolling a pivotal trial for its diagnostic aid, aiming for a 510(k) submission later this year.